ArticleEndocrine journal2026
Adipose-derived stem cell exosomes mitigate ferroptosis and enhance osteogenesis via miR-215-5p-mediated ubiquitin-specific protease 1 suppression.
Article in Endocrine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis (OP) is a metabolic bone disease characterized by impaired bone formation and excessive resorption. Ferroptosis has been implicated in osteoblast dysfunction. Adipose-derived stem cell exosomes (ADSC-exos) have emerged as promising regenerative therapies. This study investigated whether ADSC-exos alleviate ferroptosis and promote osteogenic differentiation by modulating the miR-215-5p/USP1/PTEN/AKT/GSK3β/NRF2 pathway. Human ADSC-exos were evaluated using transmission electron microscopy, nanoparticle tracking analysis, and western blot. Ferroptosis was induced in MG63 cells using ferric ammonium citrate (FAC). Cell viability, lipid peroxidation, and osteogenic differentiation were evaluated using the CCK-8 assay, C11-BODIPY staining, malondialdehyde quantification, ALP staining, and Alizarin Red S staining. The effects of ADSC-exos on PTEN ubiquitination and AKT/GSK3β/NRF2 pathway activation were assessed using western blot, RT-qPCR, and immunoprecipitation. ADSC-exos significantly improved osteoblast viability, reduced lipid peroxidation, and enhanced osteogenic differentiation in FAC-treated MG63 cells. Dual-luciferase reporter assay identified miR-215-5p as a key exosomal cargo that targets USP1. Mechanistically, ADSC-exos downregulated USP1, leading to PTEN ubiquitination and degradation, thereby activating the AKT/GSK3β/NRF2 signaling pathway. USP1 overexpression reversed the protective effects of ADSC-exos, confirming that miR-215-5p-mediated USP1 inhibition plays a crucial role in regulating ferroptosis and osteogenic differentiation. In conclusion, ADSC-exos diminish ferroptosis and enhance osteogenic differentiation by delivering miR-215-5p, which inhibits USP1, promotes PTEN ubiquitination, and activates the AKT/GSK3β/NRF2 pathway. These findings provide new insights into the mechanisms by which ADSC-exos promote bone repair and highlight their potential as an innovative treatment for OP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.